Zhong Yuan Bio-Technology Holdings Ltd. engages in the research and development of early detection kits for brain diseases, plant-derived nervonic acid health supplements and new drugs for neurological diseases. It also develops new drugs to treat cognitive impairment, brain atrophy and other encephalopathies caused by brain white matter damage. The company was founded on April 4, 2016 and is headquartered in Hong Kong.